Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Altasciences concludes US laboratory facility expansion
The newly expanded, 8,000ft2 space has a test material department. It features advanced equipment and 48 workbenches, with a wide range of services, including flow cytometry, ligand binding
The newly expanded, 8,000ft2 space has a test material department. It features advanced equipment and 48 workbenches, with a wide range of services, including flow cytometry, ligand binding
Next year, Basilea will explore multiple hypotheses through preclinical studies to identify the optimal future clinical development programme for tonabacase. Under an exclusive option, Basilea will license tonabacase
The deal will be effected by way of a three-cornered amalgamation between SecureDose, Pharmadrug and its wholly owned subsidiary. As per the terms of this transaction, all the
Designed to serve as an incubator facility, the new modern facility includes ISO 7 cGMP cleanroom suites, as well as research and development (R&D) labs. The ReadyStart cGMP
Donesta is Mithra’s investigational next-generation medicine, which contains Estetrol, to treat menopause symptoms. In July this year, Mithra and Searchlight signed a binding term sheet for a licensing
Under the deal, Moderna will utilise Caris’ library of de-identified, multi-modal data solutions generated from whole exome sequencing, whole transcriptome sequencing, and protein analyses, in addition to claims
FT011 is a first-in-class oral therapy designed to treat chronic fibrosis in multiple organs. It is currently progressing through clinical development for the treatment of scleroderma. It acts
NICE has released the final draft guidance (FDG) that suggests Brukinsa as a recommended treatment for eligible adults with untreated CLL if there is a 17p deletion or
PCI will be responsible for the formulation, packaging, and distribution of a siRNA-based investigational injectable treatment for inflammatory dermatological conditions. The organisation will carry out all these activities
Maxigesic IV, which is a combination of 1000mg paracetamol and 300mg ibuprofen solution, is given intravenously to adults for relieving mild to severe pain. It received approval for